Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia.
Faculty of Pharmacy, AIMST University, Kedah, 08100, Malaysia.
Int J Nanomedicine. 2021 Dec 2;16:7891-7941. doi: 10.2147/IJN.S328135. eCollection 2021.
Despite recent advances in the diagnosis and treatment of breast cancer (BC), it remains a global health issue affecting millions of women annually. Poor prognosis in BC patients is often linked to drug resistance as well as the lack of effective therapeutic options for metastatic and triple-negative BC. In response to these unmet needs, extensive research efforts have been devoted to exploring the anti-BC potentials of natural products owing to their multi-target mechanisms of action and good safety profiles. Various medicinal plant extracts/essential oils and natural bioactive compounds have demonstrated anti-cancer activities in preclinical BC models. Despite the promising preclinical results, however, the clinical translation of natural products has often been hindered by their poor stability, aqueous solubility and bioavailability. There have been attempts to overcome these limitations, particularly via the use of nano-based drug delivery systems (NDDSs). This review highlights the tumour targeting mechanisms of NDDSs, the advantages and disadvantages of the major classes of NDDSs and their current clinical status in BC treatment. Besides, it also discusses the proposed anti-BC mechanisms and nanoformulations of nine medicinal plants' extracts/essential oils and nine natural bioactive compounds; selected via the screening of various scientific databases, including PubMed, Scopus and Google Scholar, based on the following keywords: "Natural Product AND Nanoparticle AND Breast Cancer". Overall, these nanoformulations exhibit improved anti-cancer efficacy against preclinical BC models, with some demonstrating biocompatibility with normal cell lines and mouse models. Further clinical studies are, however, warranted to ascertain their efficacy and biocompatibility in humans.
尽管乳腺癌(BC)的诊断和治疗取得了一些进展,但它仍然是一个全球性的健康问题,每年影响着数以百万计的女性。BC 患者预后不良通常与耐药性以及转移性和三阴性 BC 缺乏有效治疗选择有关。为了应对这些未满足的需求,由于其多靶点作用机制和良好的安全性,人们投入了大量的研究工作来探索天然产物的抗 BC 潜力。各种药用植物提取物/精油和天然生物活性化合物已在 BC 的临床前模型中显示出抗癌活性。然而,尽管有很有前景的临床前结果,但天然产物的临床转化常常受到其较差的稳定性、水溶性和生物利用度的限制。人们已经尝试克服这些限制,特别是通过使用基于纳米的药物传递系统(NDDSs)。这篇综述强调了 NDDSs 的肿瘤靶向机制、主要 NDDS 类别的优缺点以及它们在 BC 治疗中的当前临床地位。此外,它还讨论了通过筛选包括 PubMed、Scopus 和 Google Scholar 在内的各种科学数据库,基于以下关键词:“天然产物 AND 纳米颗粒 AND 乳腺癌”,选择的九种药用植物提取物/精油和九种天然生物活性化合物的拟议抗 BC 机制和纳米制剂。总的来说,这些纳米制剂在对抗临床前 BC 模型方面显示出了提高的抗癌疗效,其中一些与正常细胞系和小鼠模型的生物相容性。然而,还需要进一步的临床研究来确定它们在人类中的疗效和生物相容性。